An artificial intelligence platform developed by BioNexus Labs has identified three promising antibiotic candidates effective against drug-resistant bacteria. The AI system screened over 100 million molecular compounds in under 48 hours, a process that would have taken traditional methods several years.
Two of the candidates show effectiveness against MRSA and carbapenem-resistant Enterobacteriaceae, pathogens classified by the WHO as critical priority threats. Pre-clinical testing is underway with human trials expected to begin in early 2027.
The breakthrough demonstrates AI's transformative potential in pharmaceutical research, where the traditional drug discovery pipeline averages 10 to 15 years and costs exceeding $2 billion per approved medication.
